MedTrace Logo

Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

NCT06141889 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-02-23

No results posted yet for this study

Summary

This study is a single-dose, open-label, randomized crossover and multiple-dose, open-label study to evaluate the PK of azelaprag in older adult healthy volunteers.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

Azelaprag

oral, apelin receptor (APJ) agonist

Sponsors & Collaborators

  • BioAge Labs, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick Martin, MD · BioAge Labs, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-17
Primary Completion
2024-01-26
Completion
2024-02-02

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06141889 on ClinicalTrials.gov